AREDIA

Informazioni principali

  • Nome commerciale:
  • AREDIA IV FL 90MG F 10ML
  • Forma farmaceutica:
  • PREPARAZIONE INIETTABILE
  • Composizione:
  • "90 MG/10 ML POLVERE E SOLVENTE PER SOLUZIONE PER INFUSIONE" 1 FLACONE POLVERE + 1 FIALA SOLVENTE DA 10 ML
  • Classe:
  • H
  • Tipo di ricetta:
  • Uso ospedaliero
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Farmaco allopatico

Documenti

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • AREDIA IV FL 90MG F 10ML
    Italia
  • Lingua:
  • italiano

Altre informazioni

Status

  • Fonte:
  • AIFA - Agenzia Italiana del Farmaco
  • Numero dell'autorizzazione:
  • 028150050
  • Ultimo aggiornamento:
  • 09-08-2016

Foglio illustrativo

CATEGORIA FARMACOTERAPEUTICA

Bifosfonato; inibitore del riassorbimento osseo.

INDICAZIONI

Metastasi ossee prevalentemente litiche.

Mieloma multiplo.

Ipercalcemia provocata da osteolisi neoplastica.

CONTROINDICAZIONI/EFFETTI SECONDARI

Ipersensibilita' ai componenti o a sostanze strettamente

correlate dalpunto di vista chimico.

Gravidanza e allattamento.

POSOLOGIA

S.p.m..

INTERAZIONI

Aredia puo' essere somministrato con altri farmaci senza

interazioni.

Si raccomanda di avvisare il medico di altre terapie assunte in

precedenza e di consultarlo qualora si intenda assumere altri

farmaci o vitamine.

EFFETTI INDESIDERATI

Le reazioni avverse sono solitamente modeste e transitorie.

Le reazioni piu' comuni sono di ipocalcemia sintomatica e febbre

(aumento dellatemperatura corporea di 1-2 gradi Centigradi), che

si manifesta generalmente entro 48 ore dall'infusione.

La febbre si risolve generalmentein modo spontaneo e non richiede

alcun trattamento.

L'ipocalcemia asintomatica e' rara.

Stima della frequenza: frequente >10%, occasionale >1-10%, rara

>0.001-1%, casi isolati <0.001%.

In particolare sono statiosservati i seguenti effetti

collaterali: Effetti collaterali generali.

Frequenti: febbre e sintomi simil-influenzali, talvolta

accompagnati da malessere, brividi, fatica e vampate.

Reazioni locali.

Occasionali: reazioni in sede di infusione: dolore, arrossamento,

gonfiore, indurimento, flebite o tromboflebite.

Apparato muscolo-scheletrico.

Occasionali: dolori ossei transitori, artralgia, mialgia, dolori

generalizzati.

Rari: crampi muscolari.

Apparato gastroenterico.

Occasionali: nausea, vomito.

Rari: anoressia, dolori addominali, diarrea, stipsi, dispepsia.

In casi isolati e' stata segnalata gastrite.

Sistema nervoso centrale.

Occasionali: mal di testa.

Rari: ipocalcemia sintomatica (parestesie, tetania) agitazione,

confusione, sonnolenza, insonnia, capogiri, letargia.

In casi isolati: convulsioni, allucinazioni visive.

Sangue.

Occasionali: linfocitopenia.

Rari: anemia, leucopenia.

In casi isolati: trombocitopenia.

Apparato cardiovascolare.

Rari: ipotensione, ipertensione.

Rari: ipotensione, ipertensione.

In casi isolati: insufficienza ventricolare sinistra (dispnea,

edema polmonare) insufficienza cardiaca congestizia (edema) da

carico di liquidi.

Apparato renale.

In casi isolati: ematuria, insufficienza renale acuta,

deterioramento delle condizioni renali preesistenti.

Cute e annessi.

Rari: rash, prurito.

Sensi.

In casi isolati congiuntivite, uveite (irite, iridociclite)

sclerite, episclerite, xantopsia.

Altri.

In casi isolati: riattivazione dell'erpes simplex o zoster.

Variazioni dei parametri biochimici.

Frequenti: ipocalcemia, ipofosfatemia.

Occasionali: ipomagnesemia.

Rari: iperkaliemia, ipokaliemia, ipernatriemia.

In casi isolati: alterazioni dei parametri di funzionalita'

epatica, aumento della creatinemia e della azotemia.

Molti di questi effetti indesiderati possono essere tuttavia

ascrivibili alla malattia dibase e non per tutti e' provata una

correlazione con la terapia con Aredia.

13-11-2018

Alebrije Dist Wholesale Recalls Quesillo Queseria “La Milagrosa” and “Alebrije Cheese” Because of Possible Health Risk

Alebrije Dist Wholesale Recalls Quesillo Queseria “La Milagrosa” and “Alebrije Cheese” Because of Possible Health Risk

ALEBRIJE DIST WHOLESALE is collaborating with health officials due to a positive finding of Salmonella in a sample of Quesillo “Queseria La Milagrosa”. ALEBRIJE DIST WHOLESALE is voluntarily recalling the amount of 100 kilos of Quesillo “Queseria La Milagrosa”. While “Alebrije Cheese” has not been found positive for Salmonella, ALEBRIJE DIST WHOLESALE has decided to voluntarily recall the specific 498 “Alebrije Cheese” pieces that were imported during the same period out of an abundance of caution.

FDA - U.S. Food and Drug Administration

7-11-2018

Murray Wholesale Cash & Carry recalls King Universal Butane Fuel

Murray Wholesale Cash & Carry recalls King Universal Butane Fuel

The recalled products do not have proper hazard labelling as required by the Consumer Chemicals and Containers Regulations, 2001 under the Canada Consumer Product Safety Act.

Health Canada

5-11-2018

October 31, 2018: Fullerton Man Arrested on Federal Charges Alleging Illegal Importation and Sale of Male Sexual Enhancement Drugs

October 31, 2018: Fullerton Man Arrested on Federal Charges Alleging Illegal Importation and Sale of Male Sexual Enhancement Drugs

October 31, 2018: Fullerton Man Arrested on Federal Charges Alleging Illegal Importation and Sale of Male Sexual Enhancement Drugs

FDA - U.S. Food and Drug Administration

2-10-2018

October 1, 2018: AmerisourceBergen Corp. to Pay $625 Million to Settle Civil Fraud Allegations Resulting from Its Repackaging and Sale of Adulterated Drugs and Unapproved New Drugs, Double Billing and Providing Kickbacks

October 1, 2018: AmerisourceBergen Corp. to Pay $625 Million to Settle Civil Fraud Allegations Resulting from Its Repackaging and Sale of Adulterated Drugs and Unapproved New Drugs, Double Billing and Providing Kickbacks

October 1, 2018: AmerisourceBergen Corp. to Pay $625 Million to Settle Civil Fraud Allegations Resulting from Its Repackaging and Sale of Adulterated Drugs and Unapproved New Drugs, Double Billing and Providing Kickbacks

FDA - U.S. Food and Drug Administration

19-9-2018

Modification of the existing maximum residue levels for flonicamid in various root crops

Modification of the existing maximum residue levels for flonicamid in various root crops

Published on: Tue, 18 Sep 2018 00:00:00 +0200 In accordance with Article 6 of Regulation (EC) No 396/2005, the Agriculture and Horticulture Development Council submitted a request to the competent national authority in the United Kingdom to modify the existing maximum residue levels (MRL) for the active substance flonicamid in beetroots, carrots, celeriacs/turnip rooted celeries, horseradishes, Jerusalem artichokes, parsnips, parsley roots/Hamburg roots parsley, radishes, salsifies, swedes/rutabagas, tu...

Europe - EFSA - European Food Safety Authority Publications

28-8-2018

FDA takes action against 21 websites marketing unapproved opioids as part of agency’s effort to target illegal online sales

FDA takes action against 21 websites marketing unapproved opioids as part of agency’s effort to target illegal online sales

FDA takes action against 21 websites marketing unapproved opioids as part of agency’s effort to target illegal online sales

FDA - U.S. Food and Drug Administration

23-8-2018

Companies cease sales of e-liquids with labeling or advertising that resembled kid-friendly foods following FDA, FTC warnings

Companies cease sales of e-liquids with labeling or advertising that resembled kid-friendly foods following FDA, FTC warnings

FDA announced that all 17 manufacturers, distributors, and retailers that were warned in May have stopped selling the e-liquids used in e-cigarettes with labeling or advertising resembling kid-friendly food products.

FDA - U.S. Food and Drug Administration

10-8-2018

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC is voluntarily recalling all lots, within expiry, of Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg, & 120 mg to the wholesale level. These products are being recalled as a precaution because they were manufactured using active pharmaceutical ingredients that were sourced prior to the FDA’s Import Alert of Sichuan Friendly Pharmaceutical Co., Ltd., which as a result of a 2017 inspection were found to have deficiencies with Current Good Ma...

FDA - U.S. Food and Drug Administration

1-8-2018

July 31, 2018: Three Canadians and their Company Sentenced for Wholesale Distribution of Misbranded Prescription Drugs and Money Laundering

July 31, 2018: Three Canadians and their Company Sentenced for Wholesale Distribution of Misbranded Prescription Drugs and Money Laundering

July 31, 2018: Three Canadians and their Company Sentenced for Wholesale Distribution of Misbranded Prescription Drugs and Money Laundering

FDA - U.S. Food and Drug Administration

18-7-2018

Sodium glucose co-transporter 2 inhibitors

Sodium glucose co-transporter 2 inhibitors

Safety advisory - diabetic ketoacidosis and surgical procedures

Therapeutic Goods Administration - Australia

28-6-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s efforts to collaborate with internet stakeholders to stop the illegal sale of opioids online

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s efforts to collaborate with internet stakeholders to stop the illegal sale of opioids online

FDA’s efforts to collaborate with internet stakeholders to stop the illegal sale of opioids online

FDA - U.S. Food and Drug Administration

28-6-2018

FDA Releases Guidance to Help Animal Drug Sponsors with Antimicrobial Animal Drug Sales and Distribution Reporting Requirements

FDA Releases Guidance to Help Animal Drug Sponsors with Antimicrobial Animal Drug Sales and Distribution Reporting Requirements

FDA is releasing Guidance for Industry #252. This small entity compliance guide is intended to help small businesses comply with the Antimicrobial Animal Drug Sales and Distribution final rule.

FDA - U.S. Food and Drug Administration

19-6-2018

Golden Star Wholesale  Issues Allergy Alert on Undeclared Sulfites in Dried Apricots Sour

Golden Star Wholesale Issues Allergy Alert on Undeclared Sulfites in Dried Apricots Sour

Golden Star Wholesale of Troy, MI 48084 is recalling, AL Reef Dried Apricots Sour, because it may contain undeclared sulfites. People who have an allergy or severe sensitivity to sulfites run the risk of serious or life-threatening allergic reactions if they consume this product.

FDA - U.S. Food and Drug Administration

5-6-2018

FDA takes action against 53 websites marketing unapproved opioids as part of a comprehensive effort to target illegal online sales

FDA takes action against 53 websites marketing unapproved opioids as part of a comprehensive effort to target illegal online sales

FDA announced that it has warned nine online networks, operating a total of 53 websites, that they must stop illegally marketing potentially dangerous, unapproved and misbranded versions of opioid medications, including tramadol and oxycodone.

FDA - U.S. Food and Drug Administration

21-5-2018

Melanie Wholesale Inc. Issues Allergy Alert on Undeclared Peanuts in Melanie Mini Cookies with Caramel Flavor

Melanie Wholesale Inc. Issues Allergy Alert on Undeclared Peanuts in Melanie Mini Cookies with Caramel Flavor

Melanie Wholesale Inc. of Brooklyn, NY is recalling its 17.6 oz (500g) package of “Melanie Mini Cookies with Caramel Flavor”, because they contain undeclared peanuts. People who have allergies to peanuts run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

21-5-2018

Melanie Wholesale Issues Allergy Alert on Undeclared Peanuts in Cookies

Melanie Wholesale Issues Allergy Alert on Undeclared Peanuts in Cookies

Melanie Wholesale Inc. of Brooklyn, NY is recalling its 17.6 oz (500g) package of “Melanie Liubitelskie Cookies”, because they contain undeclared peanuts. People who have allergies to peanuts run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

14-4-2018

'Rhino 69 Extreme 50000' Recalled due to Presence of Active Ingredient 'Tadalafil'

'Rhino 69 Extreme 50000' Recalled due to Presence of Active Ingredient 'Tadalafil'

AMA Wholesale Inc. (Distributor/Re-seller), is voluntarily recalling Rhino 69 Extreme 50000 capsules to the consumer level. FDA analysis found the product to be tainted with undeclared tadalafil. Tadalafil is an active ingredient in a FDA-approved prescription drug that is used for erectile dysfunction.

FDA - U.S. Food and Drug Administration

28-3-2018

DKMA Update March 2018

DKMA Update March 2018

In this issue of DKMA Update you can read about evidence; changes to Tramadol’s summary of product characteristics; inspections of the sale of OTC medicines outside pharmacies and much more

Danish Medicines Agency

1-8-2017

Withdrawal of one more batch of counterfeit packs of the schizophrenia medicine Xeplion 150 mg

Withdrawal of one more batch of counterfeit packs of the schizophrenia medicine Xeplion 150 mg

German and Danish parallel importers and the Danish Medicines Agency are now withdrawing the fourth batch of Xeplion 150 mg from wholesale distributors, hospitals and pharmacies, because the batch contains counterfeit packs.

Danish Medicines Agency

27-7-2017

Counterfeit packs of the schizophrenia medicine Xeplion 150 mg

Counterfeit packs of the schizophrenia medicine Xeplion 150 mg

One German and several Danish parallel importers and the Danish Medicines Agency have withdrawn several batches of Xeplion 150 mg from wholesale distributors, hospitals and pharmacies, because the batches contained counterfeit packs.

Danish Medicines Agency

22-9-2016

Manufacturers and wholesale distributors must be contactable outside opening hours

Manufacturers and wholesale distributors must be contactable outside opening hours

The Danish Medicines Agency will make calls to companies' main phone numbers, or emergency lines, to check that wholesale distributors and pharmaceutical manufacturers are contactable outside normal opening hours and during holidays.

Danish Medicines Agency

16-9-2016

All Danish Wholesale Distribution Authorisations now appear from EudraGMDP

All Danish Wholesale Distribution Authorisations now appear from EudraGMDP

All Danish Wholesale Distribution Authorisations have been updated to the applicable European format and entered into the common EU database, EudraGMDP, which is available to the general public.

Danish Medicines Agency

8-6-2016

Beware of falsified medicines

Beware of falsified medicines

Today, 8 June 2016, is the World Anti-Counterfeiting Day. The Danish Medicines Agency participates in this campaign to draw attention to the problem of illegal sale of falsified medicines.

Danish Medicines Agency

9-3-2015

Wholesale Distribution Authorisations and GDP certificates can now be transferred to EudraGMDP

Wholesale Distribution Authorisations and GDP certificates can now be transferred to EudraGMDP

We can now transfer Wholesale Distribution Authorisations and Good Distribution Practice certificates to EudraGMDP, a Community database in the EU.

Danish Medicines Agency

28-5-2014

More than 10,000 websites shut down in global operation

More than 10,000 websites shut down in global operation

The recent global Operation PANGEA VII resulted in the shutdown of more than 10,000 websites. The operation focused on combating online sale of counterfeit medicines and making consumers aware that they need to take care of themselves when buying medicines online. Globally, the operation led to 237 arrests, some 540,000 parcels were inspected and over 9.4 million units containing potentially life-threatening medicines were seized – worth an estimated value of more than USD 35 million. More than 10,000 we...

Danish Medicines Agency

12-2-2014

Guidelines on applications for authorisation to wholesale distribute medicines within the EU/EEA

Guidelines on applications for authorisation to wholesale distribute medicines within the EU/EEA

The Danish Health and Medicines Authority has updated the Guidelines on applications for authorisation to wholesale distribute medicines within the EU/EEA.

Danish Medicines Agency

15-1-2014

Revocation of wholesale distribution and manufacturing authorisations granted to Singad Pharma ApS

Revocation of wholesale distribution and manufacturing authorisations granted to Singad Pharma ApS

On 20 December 2013 and on 10 January 2014, the Danish Health and Medicines Authority decided to revoke the section 39 authorisations for wholesale distribution and manufacturing of medicinal products with the authorisation IDs 25081 and 25082 granted to Singad Pharma ApS (company number 255894).

Danish Medicines Agency

21-4-2006

Warning: Sale of illegal diet pills

Warning: Sale of illegal diet pills

Illegal diet pills containing the active substances ephedrine and ephedra are sold in a number of shops and on the internet. The illegal products are sold under names such as Therma Power

Danish Medicines Agency

4-9-2018

Certificates of free sale and export certificates for medical devices

Certificates of free sale and export certificates for medical devices

The TGA has introduced a new process for certificates of free sale and export certificates.

Therapeutic Goods Administration - Australia

22-7-2018

On Friday, Bayer said the permanent birth control device Essure would no longer be sold or distributed in the US for commercial reasons after 12/31/18. This came after FDA’s patient safety action in April restricting sale and distribution of the device an

On Friday, Bayer said the permanent birth control device Essure would no longer be sold or distributed in the US for commercial reasons after 12/31/18. This came after FDA’s patient safety action in April restricting sale and distribution of the device an

On Friday, Bayer said the permanent birth control device Essure would no longer be sold or distributed in the US for commercial reasons after 12/31/18. This came after FDA’s patient safety action in April restricting sale and distribution of the device and earlier agency actions

FDA - U.S. Food and Drug Administration

20-7-2018

Bayer to stop #Essure sales in the U.S.  https://go.usa.gov/xUnaA  #MedicalDevice

Bayer to stop #Essure sales in the U.S. https://go.usa.gov/xUnaA  #MedicalDevice

Bayer to stop #Essure sales in the U.S. https://go.usa.gov/xUnaA  #MedicalDevice

FDA - U.S. Food and Drug Administration